Vertex Pharmaceuticals (VRTX) Earnings Analysis

Vertex Pharmaceuticals (VRTX) next reports earnings on 2026-08-03, consensus EPS 4.74 USD. Last quarter (2026-05-04) it beat with EPS 4.47 USD vs 4.24 USD est (+5.4%). It has beaten estimates in 4/8 recent quarters (50%). Trailing P/E 27.78.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does VRTX next report earnings?

Next earnings date2026-08-03
Consensus EPS estimate4.74 USD
Revenue estimate3.23B

VRTX earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-044.47 USD4.24 USD+5.4%Beat
2026-02-125.03 USD5.11 USD-1.6%Miss
2025-11-034.8 USD4.57 USD+5%Beat
2025-08-044.52 USD4.29 USD+5.4%Beat
2025-05-054.06 USD4.25 USD-4.5%Miss
2025-02-103.98 USD4.02 USD-1%Miss
2024-11-044.38 USD4.14 USD+5.8%Beat
2024-08-01-12.83 USD-11.63 USD-10.3%Miss

Beat rate: 4/8 (50%) over reported quarters with consensus data.

VRTX valuation and analyst view

Trailing P/E27.78
Trailing EPS17.073 USD
Price / book6.20
Dividend yield0.00%
Market cap119.73B
Analyst consensusBuy (48 buy / 7 hold / 1 sell)
Avg price target529.64 USD

Related research pages

Frequently asked questions

When is Vertex Pharmaceuticals (VRTX)'s next earnings date?

Vertex Pharmaceuticals is next scheduled to report on 2026-08-03, with a consensus EPS estimate of 4.74 USD and revenue estimate of 3.23B.

Did VRTX beat earnings last quarter?

In its 2026-05-04 report, VRTX posted EPS of 4.47 USD versus a 4.24 USD estimate — a beat of 5.4%.

What is VRTX's earnings track record?

Over the last 8 reported quarters with consensus data, VRTX beat estimates 4 times (50%).

What is VRTX's current P/E ratio and EPS?

VRTX trades at a trailing P/E of 27.78 on trailing EPS of 17.073199527744983 USD.

What do analysts rate VRTX?

Analyst consensus is "Buy" across 56 ratings (0 strong buy, 48 buy, 7 hold, 1 sell, 0 strong sell). Average 12-month price target: 529.64 USD.